Mutations in the metabolic proteins IDH1 and IDH2 are associated with gliomas, acute myeloid leukemias, chondrosarcomas, intrahepatic cholangiocarcinomas, lymphomas, melanomas and colon, thyroid and prostate cancers (for review, see Krell et al., 2013). This evidence concerns the gene IDH2 and central nervous system cancer.